CD34+THY1+ synovial fibroblast subset in arthritic joints has high osteoblastic and chondrogenic potentials in vitro

Table 1 Patient characteristics

	RA	OA
Number of patients	18	52
Treatment	bDMARDs: 7	ND
	cDMARDs: 14	ND
	(MTX: 10, others: 6)	ND
Average dose of prednisolone (mg/day)	2.9 (1–10)	ND
Average C reactive protein (mg/dL)	1.20 (0.02–6.04)	ND
Proportion of SF subsets
CD34⁻THY1⁻	35.5% (8.1–83.2)	56.6% (22.1–87.1)
CD34⁻THY1⁺	24.1% (1.6–64.2)	10.2% (1.0–30.9)
CD34⁺THY1⁺	24.8% (2.1–55.7)	17.2% (0.8–56.9)

bDMARDs biologic disease-modified anti-rheumatic drugs, cDMARDs conventional disease-modified anti-rheumatic drugs, MTX methotrexate

ISSN: 1478-6362